literature

HIV mutation literature information.

Epidemiological Surveillance of HIV-1 Transmitted Drug Resistance in Spain in 2004-2012: Relevance of Transmission Clusters in the Propagation of Resistance Mutations.

PMID: 26010948 2015 PloS one

Result: Among the 44 sequences with TDR to PIs, the most common mutations were L90M (47.7%), M46L/I (33.3%), I54V/T (21.4%), and V82A (19%).

Result: It is noteworthy that several major mutations associated to high level resistance to NRTIs (K65R, L74V, Y115F, M184V and T215Y), to NNRTIs (l100I, K101E, K103N/S, V106M, Y181C, Y188L and G190A) and

Genetic Characteristics of CRF01_AE Among Newly Diagnosed HIV-1-Infected 16- to 25-Year Olds in 3 Geographic Regions of Guangxi, China.

PMID: 26020400 2015 Medicine

Abstract: The most frequent TDR mutations were M46I (2) in the Result: Two TDR mutations, M46I (2) and I50V (1) were found in the protease region, and the other eight TDR mutations, K65E(1), D67N(1), T69N(1), K103N(1), Y181C(2), G190E(1), L210W(1), and P225H(1) were from the reverse transcriptase fragment.

Discussion: The most common TDR mutations were M46I in PR and Y181C in RT.

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.

PMID: 26107265 2015 PloS one

Result: Three subjects harboured major protease mutations (V32I, M46I, I47V, L90M), selected in prior failures.

Table: M46I

Development of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, Mozambique.

PMID: 26161559 2015 PloS one

Result: PI resistance mutations were M46I (n = 5, 62.5%) and Q58E (n = 1, 12.5%), L90M (n = 2, 25.0%) (Fig 1).

Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens.

PMID: 26157536 2015 The open AIDS journal

Result: At VF, the following major treatment-emergent PI mutations or mutation mixtures were detected: M46M/I, I50I/V, I54I/M/V, and I84I/V, and the virus developed FPV RS.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

PMID: 26717411 2015 PloS one

Result: The remaining 8% of viruses with predicted intermediate or high-level LPV resistance had a combination of two or more PI DRMs with lower mutation scores, including V32I, M46I, I54M/L/V, I47V, V82S/T/M and L90M.

Table: M46I

HIV-1 subtype characteristics of infected persons living in southwestern Greece.

PMID: 26715861 2015 HIV/AIDS (Auckland, N.Z.)

Result: The 22 cases experiencing virologic failure presented with the following DRMs: M46I, F53LY, I54LTV, G73ST, L76V, V82AT, I84V, I185V, N88D, and L90M for PIs; L100I, K103NS, V179F Y181C, G190AS, V106A, K103N, and P225H for NNRTIs; and

Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.

PMID: 26695135 2015 BMC bioinformatics

Introduction: L23I, D30N, E35G, M46I/L/V, G48V, I54L, G73S/T/C/A, T74S, V82A/F/S/T, I84V, N88D/S and L90M are other mutations correlated to NFV resistance.

Introduction: The other mutations which were co-occurring with DBM and TPM included major mutations like- M46IL, I54MV, I84V, L90M, N88S, V32I,

PMID: 26572102 2015 BMC infectious diseases

Abstract: Among those genotyped, 50 % had major Protease Inhibitor mutation (M46I commonest) however 87.5 % were still susceptible to darunavir.

Result: Among PI mutations, M46I (n = 5) was the commonest mutation, followed by N88S (n = 3), I50L (n = 2), I84V (n = 2), V 82A (n = 1).

Table: M46I

HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.

PMID: 26558396 2015 PloS one

Abstract: The most prevalent PDR mutations were M46IL (1.4%), T215 revertants (0.5%), and K103NS (5.5%).

Result: Only M46IL was more frequent in recently infected individuals (p = 0.0240, Fig 2).

Result: The most prevalent PDR mutations were M46IL (1.4%) to PI, T215 revertants (0.5%) to NRTI, and K103NS (5.6%) to NNRTI.

Browser Board

Co-occurred Entities

Filtrator